Myricx Bio, a UK biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), announced...
Tubulis and Bristol Myers Squibb announced that they have entered into a strategic license agreement to develop differentiated antibody-drug conjugates (ADCs).
Through the license agreement, Bristol Myers...
Adcentrx Therapeutics, a biotechnology company focused on accelerating breakthroughs in antibody drug conjugate ("ADC") therapeutic development, and AvantGen, a leader in the use of...
